The introduction of the HEMT triple combo — elexacaftor/tezacaftor/ivacaftor (ETI) — which directly targets the defective cystic fibrosis transmembrane conductance regulator (CFTR) protein, has markedly improved clinical outcomes and quality of life in individuals with CF (42, 65, 66). This evidence concerns the gene CFTR and cystic fibrosis.